Company news

BioCryst Pharmaceuticals, Inc. news in 2026

BioCryst Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

BioCryst to Present at Upcoming Investor Conferences

November 4, 2026

BioCryst Reports Third Quarter 2026 Financial Results

November 4, 2026

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

October 29, 2026

BioCryst to Report Third Quarter 2026 Financial Results on November 4

October 21, 2026

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

October 21, 2026

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

October 5, 2026

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

August 25, 2026

BioCryst Reports Second Quarter 2026 Financial Results

August 5, 2026

BioCryst to Report Second Quarter 2026 Financial Results on August 5

July 22, 2026

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

July 15, 2026

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

June 29, 2026

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

June 12, 2026

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

May 26, 2026

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

May 13, 2026

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

May 4, 2026

BioCryst to Report First Quarter 2026 Financial Results on May 6

April 15, 2026

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

April 5, 2026

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 11, 2026

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

February 5, 2026

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

January 23, 2026

BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

January 22, 2026

Astria Stockholders Vote to Approve Acquisition by BioCryst

January 21, 2026

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

January 11, 2026

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 6, 2026

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

Calls in 2026

Decks in 2026